Details about Katharina Elisabeth Blankart

Access statistics for papers by Katharina Elisabeth Blankart.

Last updated 2025-01-08. Update your information in the RePEc Author Service.

Short-id: pfi221

Working Papers

2022

1. The Effects of Off-label Drug Use on Disability and Medical Expenditure
   NBER Working Papers, National Bureau of Economic Research, Inc
   Also in Ruhr Economic Papers, RWI - Leibniz-Institut für Wirtschaftsforschung, Ruhr-University Bochum, TU Dortmund University, University of Duisburg-Essen (2022)

2021

2. A Hard Look at “Soft” Cost‐control Measures in Healthcare Organizations: Evidence from Preferred Drug Policies in Germany
   CINCH Working Paper Series (since 2020), Duisburg-Essen University Library, DuEPublico
   Also in Working Papers, Centre for Health Economics, Monash University (2021)

Journal Articles

2024

1. Insurance barriers and inequalities in health care access: evidence from dual practice
   Health Economics Review, 2024, 14, (1), 1-16
2. The challenges of regulatory pluralism
   Health Policy, 2024, 149, (C)

2023

3. Policy as a strategy to innovate in health care? A content analysis of innovation policies in Germany, 1994–2017
   International Journal of Health Planning and Management, 2023, 38, (6), 1657-1675
4. To Seek Program Accreditation, Innovation, or Both?—Examining the Interdependencies in High-Reliability Health Care Organizations
   Schmalenbach Journal of Business Research, 2023, 75, (3), 281-302

2022

5. Arzneimittel: Placebo bei Engpassbekämpfung
   (Pharmaceuticals: Placebo in combating bottlenecks)
   Wirtschaftsdienst, 2022, 102, (4), 248-248

2021

6. Regional Innovation Systems of Medical Technology: A knowledge production function of cardiovascular research and funding in Europe
   REGION, 2021, 8, 57-81 View citations (1)

2020

7. Are patients more adherent to newer drugs?
   Health Care Management Science, 2020, 23, (4), 605-618 View citations (2)
8. Physician-Level Cost Control Measures and Regional Variation of Biosimilar Utilization in Germany
   IJERPH, 2020, 17, (11), 1-14 View citations (3)
9. The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany
   Health Economics, 2020, 29, (S1), 63-82 View citations (3)

2019

10. Improving Service Provision - The Health Care Services' Perspective
    SMR - Journal of Service Management Research, 2019, 3, (4), 163-183

2018

11. The impact of physician-level drug budgets on prescribing behavior
    The European Journal of Health Economics, 2018, 19, (2), 213-222 View citations (8)

2016

12. Dispensing behaviour of pharmacies in prescription drug markets
    Health Policy, 2016, 120, (2), 190-197
13. Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark
    Health Policy, 2016, 120, (12), 1404-1411
14. Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia
    Health Policy, 2016, 120, (10), 1115-1122 View citations (8)
15. The diffusion of generics after patent expiry in Germany
    The European Journal of Health Economics, 2016, 17, (8), 1027-1040 View citations (5)

2014

16. Analysing coverage decision-making: opening Pandora’s box?
    The European Journal of Health Economics, 2014, 15, (9), 899-906 View citations (2)
17. Early Benefit Assessment of Pharmaceuticals in Germany
    Medical Decision Making, 2014, 34, (8), 1030-1047 View citations (4)
18. Funding Decisions for Newborn Screening: A Comparative Review of 22 Decision Processes in Europe
    IJERPH, 2014, 11, (5), 1-28

2013

19. Link between Process and Appraisal in Coverage Decisions
    Medical Decision Making, 2013, 33, (8), 1009-1025
20. Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis
    Health Policy, 2013, 112, (3), 187-196 View citations (6)

2012

21. A systematic review of coverage decision-making on health technologies—Evidence from the real world
    Health Policy, 2012, 107, (2), 218-230 View citations (14)

2011

22. A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention
    Health Policy, 2011, 101, (3), 290-299 View citations (5)